-
Posted by
Two Blokes Apr 17 -
Filed in
Stock
-
2 views
PNKP TechnologyShown in Past Study to Increase Survival Rate in Colorectal Cancer Bearing Mice VANCOUVER, BC / ACCESS Newswire / April 17, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company")is pleased to announce that it has entered into an agreement with Dalton Pharma Services ("Dalton") dated April 8, 2025, for the custom synthesis of a heavy labelled isotope of its exclusively-licensed Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor (the "Technology"), based on a nanoparticle formulation of second-generation PNKP inhibitor, which when used as a monotherapeutic, was shown to increase the survival time of PTEN-deficient colorectal cancer tumor-bearing mice in a June 2021 study1 conducted by researchers at the University of Alberta ("Study"). This agreement with Dalton marks a critical step toward advancing IND-enabling animal model research, as the labelled compound will be used in upcoming ADME (Absorption, Distribution, Metabolism, and Excretion) studies.
